Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04221750). This is a study registration, not published results. Lead sponsor: VA Office of Research and Development. Recruitment status: COMPLETED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 114 participants (ACTUAL). Conditions: Frailty, Sarcopenic Obesity, Aging. Interventions: BEHAVIORAL: Lifestyle therapy; DRUG: Metformin Hydrochloride; DRUG: Placebo; BEHAVIORAL: Healthy Lifestyle. Primary outcome measures: Change in the Modified Physical Performance Test (PPT) , 6 months. Brief summary: The continuing increase in prevalence of obesity in older adults including many older Veterans has become a major health concern. The clinical trial will test the central hypothesis that a multicomponent intervention consisting of lifestyle therapy (diet-induced weight loss and exercise training) plus metformin will be the most effective strategy for reversing sarcopenic obesity and frailty in older Veterans with obesity.